Danaher Co. (NYSE:DHR) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lowered its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 297,414 shares of the conglomerate's stock after selling 5,629 shares during the period. PNC Financial Services Group Inc.'s holdings in Danaher were worth $68,271,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Camden National Bank raised its position in shares of Danaher by 285.0% in the fourth quarter. Camden National Bank now owns 7,227 shares of the conglomerate's stock valued at $1,659,000 after buying an additional 5,350 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its stake in Danaher by 5.0% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,340,857 shares of the conglomerate's stock worth $332,929,000 after acquiring an additional 63,291 shares during the period. Machina Capital S.A.S. raised its holdings in Danaher by 455.4% in the 4th quarter. Machina Capital S.A.S. now owns 10,552 shares of the conglomerate's stock valued at $2,422,000 after acquiring an additional 8,652 shares during the last quarter. Mesirow Financial Investment Management Inc. lifted its stake in shares of Danaher by 3.3% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 15,171 shares of the conglomerate's stock worth $3,481,000 after purchasing an additional 490 shares during the period. Finally, Berkshire Asset Management LLC PA boosted its holdings in shares of Danaher by 4.5% during the fourth quarter. Berkshire Asset Management LLC PA now owns 1,300 shares of the conglomerate's stock worth $320,000 after purchasing an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity

In other news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company's stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $212.35 on Friday. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The stock has a market capitalization of $151.77 billion, a P/E ratio of 40.22, a P/E/G ratio of 2.66 and a beta of 0.82. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The business has a 50-day moving average of $222.51 and a two-hundred day moving average of $242.82.

Remove Ads

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the company earned $2.09 earnings per share. On average, equities research analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Friday, March 28th. This is an increase from Danaher's previous quarterly dividend of $0.27. Danaher's dividend payout ratio is presently 24.24%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Wells Fargo & Company reduced their target price on Danaher from $280.00 to $240.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. StockNews.com lowered shares of Danaher from a "buy" rating to a "hold" rating in a report on Saturday, December 14th. The Goldman Sachs Group set a $250.00 target price on shares of Danaher in a report on Wednesday, January 15th. Raymond James reaffirmed a "market perform" rating on shares of Danaher in a research note on Monday, February 3rd. Finally, Scotiabank assumed coverage on shares of Danaher in a research note on Monday, December 23rd. They set a "sector perform" rating and a $265.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.